| Literature DB >> 25099441 |
Margaret A Tempero1, Mokenge P Malafa1, Stephen W Behrman1, Al B Benson1, Ephraim S Casper1, E Gabriela Chiorean1, Vincent Chung1, Steven J Cohen1, Brian Czito1, Anitra Engebretson1, Mary Feng1, William G Hawkins1, Joseph Herman1, John P Hoffman1, Andrew Ko1, Srinadh Komanduri1, Albert Koong1, Andrew M Lowy1, Wen Wee Ma1, Nipun B Merchant1, Sean J Mulvihill1, Peter Muscarella1, Eric K Nakakura1, Jorge Obando1, Martha B Pitman1, Sushanth Reddy1, Aaron R Sasson1, Sarah P Thayer1, Colin D Weekes1, Robert A Wolff1, Brian M Wolpin1, Jennifer L Burns1, Deborah A Freedman-Cass1.
Abstract
The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize major discussion points from the 2014 NCCN Pancreatic Adenocarcinoma Panel meeting. The panel discussion focused mainly on the management of borderline resectable and locally advanced disease. In particular, the panel discussed the definition of borderline resectable disease, role of neoadjuvant therapy in borderline disease, role of chemoradiation in locally advanced disease, and potential role of newer, more active chemotherapy regimens in both settings.Entities:
Mesh：
Year: 2014 PMID： 25099441 DOI： 10.6004/jnccn.2014.0106
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908